<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32306171</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>267</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease.</ArticleTitle><Pagination><StartPage>2272</StartPage><EndPage>2280</EndPage><MedlinePgn>2272-2280</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-09838-9</ELocationID><Abstract><AbstractText>To investigate the prognostic role and the major determinants of serum phosphorylated neurofilament heavy -chain (pNfH) concentration across a large cohort of motor neuron disease (MND) phenotypes. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum pNfH concentration in 219 MND patients consecutively enrolled in our tertiary MND clinic. A multifactorial analysis was carried out to investigate the major clinical determinants of serum pNfH. Kaplan-Meier survival curves and Cox regression analysis were performed to explore the prognostic value of serum pNfH. Serum pNfH levels were not homogenous among MND phenotypes; higher concentrations in pyramidal, bulbar, and classic phenotypes were observed. C9orf72-MND exhibited higher pNfH concentrations compared to non-C9orf72 MND. Multiple linear regression analysis revealed mean MEP/cMAP and disease progression rate as the two major predictors of serum pNfH levels (R<sup>2</sup>&#x2009;=&#x2009;0.188; p&#x2009;&#x2264;&#x2009;0.001). Kaplan-Meier curves showed a significant difference of survival among MND subgroups when divided into quartiles based on pNfH concentrations, log-rank X<sup>2</sup>&#x2009;=&#x2009;53.0, p&#x2009;&#x2264;&#x2009;0.0001. Our study evidenced that higher serum pNfH concentration is a negative independent prognostic factor for survival. In Cox multivariate model, pNfH concentration showed the highest hazard ratio compared to the other factors influencing survival included in the analysis. pNfH differs among the MND phenotypes and is an independent prognostic factor for survival. This study provides supporting evidence of the role of pNfH as useful prognostic biomarker for MND patients. Neurofilament measurements should be considered in the future prognostic models and in clinical trials for biomarker-based stratification, and to evaluate treatment response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falzone</LastName><ForeName>Yuri Matteo</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Neuropathology Unit, San Raffaele Scientific Institute, via Olgettina 48, 20132, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domi</LastName><ForeName>Teuta</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Neuropathology Unit, San Raffaele Scientific Institute, via Olgettina 48, 20132, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agosta</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuroscience, Neuroimaging Research Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Neuropathology Unit, San Raffaele Scientific Institute, via Olgettina 48, 20132, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schito</LastName><ForeName>Paride</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Neuropathology Unit, San Raffaele Scientific Institute, via Olgettina 48, 20132, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazio</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Carro</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbieri</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comola</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leocani</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comi</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrera</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Genetics and Cell Biology, Unit of Genomics for Human Disease Diagnosis, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuroscience, Neuroimaging Research Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurophysiology Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quattrini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Neuropathology Unit, San Raffaele Scientific Institute, via Olgettina 48, 20132, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Neuropathology Unit, San Raffaele Scientific Institute, via Olgettina 48, 20132, Milan, Italy. riva.nilo@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy. riva.nilo@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Milan, Italy. riva.nilo@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy. riva.nilo@hsr.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>#RF-2011-02351193</GrantID><Agency>Italian Ministry of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">FTD</Keyword></KeywordList><CoiStatement>On behalf of all authors, the corresponding author states that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32306171</ArticleId><ArticleId IdType="pmc">PMC7166001</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09838-9</ArticleId><ArticleId IdType="pii">10.1007/s00415-020-09838-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A. Recent advances in amyotrophic lateral sclerosis. J Neurol. 2016;263(6):1241&#x2013;1254. doi: 10.1007/s00415-016-8091-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8091-6</ArticleId><ArticleId IdType="pmc">PMC4893385</ArticleId><ArticleId IdType="pubmed">27025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G, Group Ps Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, Brunetti M, Ossola I, Lo Presti A, Cammarosano S, Canosa A, Chio A. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry. 2015;86(2):168&#x2013;173. doi: 10.1136/jnnp-2013-307223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307223</ArticleId><ArticleId IdType="pubmed">24769471</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, Williams KL, Fifita JA, Tarr IS, O'Connor J, Rowe DB, Nicholson GA, Blair IP. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. 2017;92(3):259&#x2013;266. doi: 10.1111/cge.12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12973</ArticleId><ArticleId IdType="pubmed">28105640</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, Hu W, Gearing M, Glass JD. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology. 2016;87(10):1024&#x2013;1030. doi: 10.1212/WNL.0000000000003067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003067</ArticleId><ArticleId IdType="pmc">PMC5027809</ArticleId><ArticleId IdType="pubmed">27488601</ArticleId></ArticleIdList></Reference><Reference><Citation>Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, Tsuda M, Al-Chalabi A. A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry. 2016;87(12):1361&#x2013;1367. doi: 10.1136/jnnp-2015-312908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312908</ArticleId><ArticleId IdType="pmc">PMC5136716</ArticleId><ArticleId IdType="pubmed">27378085</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt J, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Korner S, Ringer TM, Rodiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chio A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Li DW, Ren H, Jeromin A, Liu M, Shen D, Tai H, Ding Q, Li X, Cui L. Diagnostic performance of neurofilaments in Chinese patients with amyotrophic lateral sclerosis: a prospective study. Front Neurol. 2018;9:726. doi: 10.3389/fneur.2018.00726.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00726</ArticleId><ArticleId IdType="pmc">PMC6121092</ArticleId><ArticleId IdType="pubmed">30210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, von Arnim CA, Bohm S, Kassubek J, Kubisch C, Lule D, Muller HP, Muche R, Pinkhardt E, Oeckl P, Rosenbohm A, Anderl-Straub S, Volk AE, Weydt P, Ludolph AC, Otto M. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87(1):12&#x2013;20. doi: 10.1136/jnnp-2015-311387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Taga A, Maragakis NJ. Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Rev Neurother. 2018;18(11):871&#x2013;886. doi: 10.1080/14737175.2018.1530987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2018.1530987</ArticleId><ArticleId IdType="pubmed">30273061</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJP, Wilkinson ID, Jenkins TM, Shaw PJ. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 2019;10:291. doi: 10.3389/fneur.2019.00291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti A, Riva N, Pesca M, Iannaccone S, Cannistraci CV, Corbo M, Previtali SC, Quattrini A, Alessio M. Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim Biophys Acta. 2014;1842(1):99&#x2013;106. doi: 10.1016/j.bbadis.2013.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.10.013</ArticleId><ArticleId IdType="pubmed">24184715</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2018;9:1167. doi: 10.3389/fneur.2018.01167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91(2):494&#x2013;496. doi: 10.1016/j.neuron.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.07.007</ArticleId><ArticleId IdType="pubmed">27477021</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, Claeys KG, Herbst V, Brix B, Van Damme P, Poesen K. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(4):367&#x2013;373. doi: 10.1136/jnnp-2017-316605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, Prell T, Ringer TM, Rhode H, Stevens O, Claeys KG, Couwelier G, D'Hondt A, Lamaire N, Tilkin P, Van Reijen D, Gourmaud S, Fedtke N, Heiling B, Rumpel M, Rodiger A, Gunkel A, Witte OW, Paquet C, Vandenberghe R, Grosskreutz J, Van Damme P. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302&#x2013;2309. doi: 10.1212/WNL.0000000000004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, Dedeene L, De Vocht J, Oldoni E, Goris A, Van Den Bosch L, Depreitere B, Claeys KG, Tournoy J, Van Damme P, Poesen K. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol. 2019;45(3):291&#x2013;304. doi: 10.1111/nan.12511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan KB, Glass JD, Crook JE, Yang C, Thomas CS, Desaro P, Johnston A, Overstreet K, Kelly C, Polak M, Shaw G. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(4):467&#x2013;472. doi: 10.1136/jnnp-2012-303768s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303768s</ArticleId><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, Pearce N, Kuhle J, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Greensmith L, Malaspina A. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86(5):565&#x2013;573. doi: 10.1136/jnnp-2014-307672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, Toffanin E, Cagnin A, Briani C, Pegoraro E, Soraru G. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74(5):525&#x2013;532. doi: 10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, Scialo C, Soraru G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Chio A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurro MR, Sabatelli M, Riva N, Logroscino G, Messina S, Fini N, Mandrioli J. Factors predicting survival in ALS: a multicenter Italian study. J Neurol. 2017;264(1):54&#x2013;63. doi: 10.1007/s00415-016-8313-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8313-y</ArticleId><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011;70(1):79&#x2013;83. doi: 10.1002/ana.22380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22380</ArticleId><ArticleId IdType="pubmed">21437935</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Mora G, Soraru G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(2):155&#x2013;164. doi: 10.1016/S1474-4422(18)30406-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30406-X</ArticleId><ArticleId IdType="pubmed">30554828</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(Pt 3):847&#x2013;852. doi: 10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1&#x2013;2):9&#x2013;14. doi: 10.3109/21678421.2013.805784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobaGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3&#x2013;4):153&#x2013;174. doi: 10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Falini A, Inuggi A, Gonzalez-Rosa JJ, Amadio S, Cerri F, Fazio R, Del Carro U, Comola M, Comi G, Leocani L. Cortical activation to voluntary movement in amyotrophic lateral sclerosis is related to corticospinal damage: electrophysiological evidence. Clin Neurophysiol. 2012;123(8):1586&#x2013;1592. doi: 10.1016/j.clinph.2011.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2011.12.013</ArticleId><ArticleId IdType="pubmed">22326728</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(1):17&#x2013;28. doi: 10.1080/14660820410020600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410020600</ArticleId><ArticleId IdType="pubmed">16036422</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Group CONS. Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, Pastor P, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Benatar M, Silani V, Glass JD, Floeter MK, Jeromin A, Boylan KB, Petrucelli L. Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol. 2017;82(1):139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Ferraro PM, Riva N, Spinelli EG, Domi T, Carrera P, Copetti M, Falzone Y, Ferrari M, Lunetta C, Comi G, Falini A, Quattrini A, Filippi M. Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. 2017;57:206&#x2013;219. doi: 10.1016/j.neurobiolaging.2017.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.024</ArticleId><ArticleId IdType="pubmed">28666709</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, Turner MR. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2(7):748&#x2013;755. doi: 10.1002/acn3.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.212</ArticleId><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandery S, Vincent T, Camu W. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2019 doi: 10.1111/ene.14063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14063</ArticleId><ArticleId IdType="pubmed">31437330</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Ren Y, Zhu W, Yang F, Zhang X, Huang X. Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J Neurol Sci. 2016;367:269&#x2013;274. doi: 10.1016/j.jns.2016.05.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.05.062</ArticleId><ArticleId IdType="pubmed">27423602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011;117(3):528&#x2013;537. doi: 10.1111/j.1471-4159.2011.07224.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07224.x</ArticleId><ArticleId IdType="pmc">PMC3076545</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>